No image available
Long-term Outcome After Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
by Marie Robin, Liesbeth Cornelia de Wreede, Christine Wolschke, Johannes Schetelig, Diderik-Jan Eikema, Maria Teresa van Lint, Nina Simone Knelange, Dietrich W. Beelen, Arne Jörn Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Andreas Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Alekxandar Radujkovic, Donal P. McLornan, Yves Chalandon, Nicolaus Kröger · 2019
Book is in your Library
ISBN: Unavailable
Category: Unavailable
Page count: Unavailable
Abstract: Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged